AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 41 min read$CODX

Co-Diagnostics, Inc. (CODX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Co-Diagnostics, Inc. (the “Company”) and Brian Brown, the Company’s Chief Financial Officer, determi

Original reporting
SEC EDGAR 8-K
Published Sep 4, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CODX
Neutral
medium confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The filing is a primary disclosure of executive turnover, a standard corporate action for a micro‑cap.

02

Market read

Limited; primarily relevant to CODX shareholders and sector analysts.

03

What to watch

Bohrer's prior experience at Workfront and EY may bring new accounting rigor or cost controls.

Relevance 6/10Novelty 5/10Timing: post‑filing Sep 4 2026

Background

Co‑Diagnostics filed a Form 8‑K announcing the separation of its CFO and the appointment of a new CFO with a salary increase.

Company-level read

Ticker impact

$CODXNeutralMedium confidence
Context

SEC 8‑K reports CFO Brian Brown's departure and promotion of Daniel Bohrer to CFO with salary increase.

Expected impact

Potential short‑term volatility; limited upside unless new CFO signals strategic change.

Evidence & confidence

CFO changes are material but typical for micro‑caps; no immediate catalyst beyond the filing.

Market effects

Sector

Minimal impact on diagnostics sector; similar firms may see slight attention to governance.

Regional

U.S. micro‑cap market; no broader regional effect.

Global

Low

Counterpoint

What could challenge this read

The CFO change could be a catalyst for a strategic shift that the market undervalues.

Key entities

  • company
    Co‑Diagnostics, Inc.

    NASDAQ‑listed diagnostics company (ticker CODX).

  • person
    Brian Brown

    Outgoing Chief Financial Officer.

  • person
    Daniel Bohrer

    Incoming Chief Financial Officer.

Read at source← All news

Related articles

AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics, Inc. (CODX): Results of Operations and Financial Condition

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min
AUG 6
$CODXMed

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

prnewswire.com2 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min